Loading...
Loading...
NEW YORK, NY · CIK 0001601086
New positions
158
Added to
69
Trimmed
83
Exited
148
Clone performance through .
Source: SEC 13F-HR filing filed on 2026-11-16 ·View on SEC.gov →
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SUPNSUPERNUS PHARMACEUTICALS | $109.67M | 3.68% | -3.7% |
| 2 | AGIOAGIOS PHARMACEUTICALS INC | $85.72M | 2.87% | +7.4% |
| 3 | PTCTPTC THERAPEUTICS INC | $84.05M | 2.82% | +21.1% |
| 4 | NBIXNEUROCRINE BIOSCIENCES INC | $80.18M | 2.69% | +5.5% |
| 5 | CYTKCYTOKINETICS INC | $77.79M | 2.61% | -1.8% |
| 6 | TVTXTRAVERE THERAPEUTICS INC | $75.94M | 2.55% | -18.0% |
| 7 | RIGLRIGEL PHARMACEUTICALS INC | $73.96M | 2.48% | -8.1% |
| 8 | INCYINCYTE CORP | $72.82M | 2.44% | -33.3% |
| 9 | IRWDIRONWOOD PHARMACEUTICALS INC | $59.55M | 2.00% | +7.7% |
| 10 | IMVTIMMUNOVANT INC | $58.72M | 1.97% | +0.1% |
| Stock | Value | Shares |
|---|---|---|
| TLXTELIX PHARMACEUTICAL LTD | $18.32M | 1,670,000 |
| GEHCGE HEALTHCARE TECHNOLOGIES I | $16.30M | 249,374 |
| BNTXBIONTECH SE | $16.12M | 164,000 |
| SPSCSPS COMM INC | $15.73M | 190,814 |
| DKSDICKS SPORTING GOODS INC | $13.07M | 97,308 |
| LIONLIONSGATE STUDIOS CORP | $8.27M | 738,655 |
| MBCMASTERBRAND INC | $7.25M | 1,036,000 |
| XMTRXOMETRY INC | $5.52M | 53,686 |
| METAMETA PLATFORMS INC | $4.30M | 5,932 |
| KEELKEEL INFRASTRUCTURE CORP | $3.66M | 1,036,000 |
As of Q3 2026, ARMISTICE CAPITAL, LLC reported a portfolio value of $2.98B across 333 positions in their 13F filing.
ARMISTICE CAPITAL, LLC's largest holding is SUPN with a position worth $109.67M. Their top holdings include SUPN, AGIO, PTCT, NBIX, CYTK.
In Q3 2026, ARMISTICE CAPITAL, LLC made the following changes to their portfolio: 158 new positions, 148 positions sold out, 69 positions increased, 83 positions reduced.
ARMISTICE CAPITAL, LLC files quarterly 13F reports with the SEC, disclosing their long positions in U.S. equities. These filings are due within 45 days of the quarter end and provide transparency into their investment strategy and portfolio allocation.
One weekly email with notable insider buys, sells and congressional disclosures. Unsubscribe anytime.